(S)-N-ethyl-N-methyl-1-phenylethylamine | 79806-75-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-N-ethyl-N-methyl-1-phenylethylamine
• 英文别名: (1S)-N-ethyl-N-methyl-1-phenylethanamine
• CAS: 79806-75-0
• 化学式: C₁₁H₁₇N
• 分子量: 163.263
• InChiKey: JGNLCAPCURRRBI-JTQLQIEISA-N

物化性质

• 沸点：
  197.8±9.0 °C(Predicted)
• 密度：
  0.908±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 N-乙基-1-苯基乙胺 在 甲酸 作用下， 生成 (S)-N-ethyl-N-methyl-1-phenylethylamine
  参考文献：
  名称：

  Studies on the configuration of nitrogenous stereogenic centres in adducts of rhodium(II) tetraacylates with chiral amines: the application of 1H and 13C NMR spectroscopy

  摘要：

  The H-1 and C-13 NMR spectra of enantiomerically pure amines (S)-N,N-dimethyl-1-phenylethylamine, (S)-N-methyl-1-phenylethylamine, (S)-N-ethyl-1-phenylethylamine and (S)-N-ethyl-N-methyl-1-phenylethylamine in the presence of a twofold molar excess of dirhodium(II) tetratrifluoroacetate and dirhodium(II) Mosher's acid derivatives [(4S) and (4R)] were measured in CDCl3 as a solvent. The amines having various substituents at the nitrogen atom (H, CH3 and CH2CH3) formed in such conditions as an equilibrium mixture of CSNR and CSNS 1: 1 adducts. The signals of both diastereoisomers were observed in NMR spectra at either room temperature (303 K) or moderately decreased temperatures (263-273 K). The rates of mutual diastereoisomer conversion were estimated by selective inversion recovery experiments and varied from less than 0.1 to ca. 10 s(-1), depending on the ligand and temperature. Analysis Of C-13 NMR data and NOE experimental data resulted in the unambiguous determination of the configuration at the nitrogen atom with respect to the carbon stereogenic centre.Modelling of adduct structures and calculations of molecular energy and NMR parameters (GIAO) using Density Functional Theory (DFT) were performed in order to Support the experimental findings. The calculations were carried out using 3-21G//B3LYP (structure optimizing) and 311G(2d,p)/LanL2DZ//B3LYP theory levels (molecular energy and NMR shielding). (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2009.09.021

文献信息

• COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210147383A1

  公开（公告）日：2021-05-20

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR 6 R 6 or C═O; Ring A is: and R 1 , R 2 , R 3 , R 4 , R 5 , m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  公开的化合物为Formula (I)的化合物或其盐，其中：Z为CR6R6或C═O；环A为：而R1、R2、R3、R4、R5、m和n在此处有定义。还公开了使用这些化合物抑制Helios蛋白的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面非常有用。
• 3-SUBSTITUTED-6-ARYL PYRIDINES
  申请人：Hutchinson Alan J.

  公开号：US20110281837A1

  公开（公告）日：2011-11-17

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I的3-取代-6-芳基吡啶化合物：其中R1、R2、R3、R8、R9、A和Ar的定义在此处。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及将这些化合物用于治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体定位的探针。
• 3-Substituted-6-Aryl Pyridines
  申请人：Hutchison Alan J.

  公开号：US20090176980A1

  公开（公告）日：2009-07-09

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I中的3-取代-6-芳基吡啶化合物： 其中R1、R2、R3、R8、R9、A和Ar在此定义。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的药物组合物，以及在治疗各种炎症，心血管和免疫系统疾病中使用这些化合物的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体的定位探针。
• US7342115B2
  申请人：——

  公开号：US7342115B2

  公开（公告）日：2008-03-11
• US7863454B2
  申请人：——

  公开号：US7863454B2

  公开（公告）日：2011-01-04